The pharmaceutical industry is at a crossroads: Research and Development costs continue to rise, whilst the pipeline of ‘blockbuster’ drugs is looking decidedly sparse for many of the major pharmaceutical companies. This state of affairs is compounded by the high attrition rates (>80%) of drug candidates, when they get to clinical trials. Thus, the major pharmaceutical companies are keen to apply new technologies that allow faster decision making (proceed with development of a drug candidate, or stop at an earlier point) and ultimately increase the number of new medicines that reach the marketplace.